Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

ABSTRACT:

SUBMITTER: Maiti A 

PROVIDER: S-EPMC7927994 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature